Idiopathic normal pressure hydrocephalus (iNPH) is a subtype of dementia that may be successfully treated with cerebrospinal fluid (CSF) diversion. Recently, magnetic resonance imaging (MRI) using a MRI contrast agent as a CSF tracer revealed impaired clearance of the CSF tracer from various brain regions such as the entorhinal cortex of iNPH patients. Hampered clearance of waste solutes, for example, soluble amyloid-β, may underlie neurodegeneration and dementia in iNPH. The goal of the present study was to explore whether iNPH is associated with altered subcellular distribution of aquaporin-4 (AQP4) water channels, which is reported to facilitate CSF circulation and paravascular glymphatic drainage of metabolites from the brain parenchyma. Cortical brain biopsies of 30 iNPH patients and 12 reference individuals were subjected to AQP4 immunogold cytochemistry. Electron microscopy revealed significantly reduced density of AQP4 water channels in astrocytic endfoot membranes along cortical microvessels in patients with iNPH versus reference subjects. There was a significant positive correlation between density of AQP4 toward endothelial cells (perivascular) and toward parenchyma, but the reduced density of AQP4 toward parenchyma was not significant in iNPH. We conclude that perivascular AQP4 expression is attenuated in iNPH, potentially contributing to impaired glymphatic circulation, and waste clearance, and subsequent neurodegeneration. Hence, restoring normal perivascular AQP4 distribution may emerge as a novel treatment strategy for iNPH.
| INTRODUCTION
The brain-wide glia-lymphatic or glymphatic fluid circulation system has emerged as an important mechanism for supporting brain metabolism and clearance of waste products (Iliff et al., 2012; Mestre, Kostrikov, Mehta, & Nedergaard, 2017) . Magnetic resonance imaging (MRI) has revealed that idiopathic normal pressure hydrocephalus (iNPH) patients have impaired glymphatic circulation in the paravascular space and within the brain parenchyma (Eide & Ringstad, 2018; Ringstad, Vatnehol, & Eide, 2017) . iNPH is a subtype of dementia that may be alleviated by diversion of cerebrospinal fluid (CSF) (Adams, Fisher, Hakim, Ojemann, & Sweet, 1965) , though CSF diversion provides variable and temporary symptom relief (Eide & Sorteberg, 2016) . The mechanisms underlying impaired fluid turnover in this patient group are unknown.
Experimental studies in rodents suggest that glymphatic circulation is dependent on aquaporin-4 (AQP4) water channels, which are located in glial cell membranes, and highly concentrated in perivascular glial endfeet (Eidsvaag, Enger, Hansson, Eide, & Nagelhus, 2017; Nagelhus et al., 1999; Nielsen et al., 1997) . Others have disputed a role of AQP4 in transport of solutes within the brain parenchyma (Smith, Yao, Dix, Jin, & Verkman, 2017) . Light microscopic (LM) observations in tissue from iNPH patients suggest a loss of perivascular AQP4 (Eide & Hansson, 2018) , which might contribute to the reduced glymphatic clearance seen in these patients (Eide & Ringstad, 2018; Ringstad et al., 2017) .
In the present study, we used semiquantitative immunogold electron microscopy (EM) to characterize and quantify AQP4 subcellular distribution in brain tissue from 30 iNPH patients and 12 reference (REF) patients (Eidsvaag et al., 2017) , and provide evidence of reduced perivascular AQP4 in iNPH.
| MATERIALS AND METHODS

| Ethical approvals
The Regional Committee for Medical and Health Research Ethics of Health Region South-East, Norway, approved the study, as well as did Oslo University Hospital. Patients were included after oral and written informed consent. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
| Experimental design
The study was prospective and observational, and included consecutive iNPH and REF patients. This study design made randomization of patients not relevant, neither was a priori sample size calculation needed. The analyzer assessing AQP4 distribution by EM was blinded to patient data and diagnosis.
| Participants
| iNPH patients
Consecutive iNPH patients referred to the Department of neurosurgery, Oslo University Hospital -Rikshospitalet, Oslo, Norway, were included based on symptoms and clinical findings indicative of iNPH and imaging findings of ventriculomegaly. The clinical severity was graded according to a previously described NPH grading scale (15 possible scores ranging from 3 to 15), which assesses the combined severity of gait disturbance, urinary incontinence, and dementia (Eide & Sorteberg, 2010 .
| REF patients
Apparently normal brain tissue was sampled from patients undergoing neurosurgery, and in whom removal of normal brain tissue was 
| Management of iNPH patients
The diagnostic work-up of iNPH patients included a three day stay in the neurosurgery department. Day 1 (day of admittance), clinical neurological assessment and MRI were performed if not done recently.
Day 2, an intracranial pressure (ICP) sensor was implanted and brain biopsy performed. Day 3, following overnight ICP monitoring, it was determined whether the patient should be offered surgical treatment.
The diagnostic procedure was done in the operation room. In local anesthesia, a skin incision was done frontally on the right side, a small burr hole about 1 cm in diameter was made, the dura opened, and the brain surface exposed. A disposable Nashold Biopsy needle (Integra Radionics, Burlington, MA) was introduced immediately below the cortical surface and a biopsy (0.9 mm × 10 mm) aspirated through the needle. Then, a solid ICP sensor (Codman MicroSensor™, Johnson & Johnson, Raynham, MA) was tunneled subcutaneously, zeroed against the atmospheric pressure and introduced 1-2 cm into the frontal cortex parenchyma via the small opening that was established by the biopsy. The overnight monitoring and subsequent analysis of ICP scores was undertaken as previously described in detail (Eide & Sorteberg, 2010 
| Post-embedding electron microscopic procedure
Detailed technical procedures for the handling, processing, and analysis of the frontal cortex biopsies have been reported (Eide & Hansson, 2018; Eidsvaag et al., 2017) . In brief, the dissected brain material was fixed by immersion in 0.1 M phosphate buffer containing 4% paraformaldehyde and 0.25% glutaraldehyde and cut into small specimens (typically 0.5 mm × 0.5 mm × 1 mm). The EM specimens were subjected to freeze substitution and infiltration in Lowicryl HM20 resin (Polysciences Inc., Warrington, PA, Cat 15924) (Schwarz and Humbel, 1989) . A Reichert ultramicrotome (Reichert Techn., Wien, Austria) was used for cutting sections of 80 nm thicknesses, which were mounted on nickel grids and further processed for immunogold cytochemistry.
The sections were incubated in the following solutions: (a) 50 mM glycine in tris buffer (5 mM) containing 0.01% Triton X-100 and 50 mM NaCl (TBST; 10 min); (b) 2% human serum albumin (HSA) in TBST (10 min); (c) primary antibody (anti-AQP4 from Sigma-Aldrich; 25 μg/ml) diluted in the solution used in the preceding step (overnight); (d) same solution as in step 2 (10 min × 2); and (e) goldconjugated IgG (GAR15 nm, Abcam, Cambridge, UK), diluted 1:20 in TBST containing 2% HSA and polyethylene glycol (0.5 mg/ml, 1 hr).
Sections were then counterstained with 1% uranyl acetate and 0.3% lead citrate.
| Quantification of AQP4 immunogold distribution
The images were recorded with a FEI Tecnai™ 12 transmission electron microscope (FEI Company, Hillsboro, OR) at a nominal magnification of 43,000. Micrographs were saved as 2048 × 2048 pixels. Eight bit images were subsequently analyzed using a MATLAB based toolbox (Enger, 2017) , designed for automatic evaluation of immunogoldlabeled membranes (Supporting Information Figure S1 ).
We analyzed linear density of AQP4 toward endothelium and parenchyma (neuropil).
| Statistical analysis
Statistical analyses were performed using the SPSS software version 22 (IBM Corporation, Armonk, NY). Differences between categorical data were determined using Pearson chi-square test, and differences between continuous data were determined using independent samples t test. Statistical significance was accepted at the .05 level (two-tailed).
| RESULTS
| Study cohort
The present study includes tissue from 30 iNPH and 12 REF patients.
Demographic information about the patient cohorts is provided in Table 2 shows the pulsatile and static ICP scores for the iNPH group, which had significantly increased pulsatile and static ICP scores in the 26 patients undergoing surgery, as compared with those not being operated. Total NPH score (24 months) 13 (9-15)
| ICP scores in iNPH patients
| Subcellular distribution of AQP4 immunogold labeling
Categorical data presented as numbers; continuous data presented as mean AE standard deviation (SD). NPH scores presented as median with ranges in parenthesis. Significant differences between continuous variables were determined by independent samples t test, and differences between categorical data were determined by Pearson chi-square test. neuropil, respectively) were sampled ( Figure 3a ; Table 3 ). AQP4 labeling in endfoot membranes facing neuropil was not significantly different between iNPH and REF subjects (linear density of gold particles per μm 6.8 AE2.7 vs. 8.3 AE2.3, p = .11; Figure 3b ; Table 3 ).
The AQP4 polarization index, that is, ratio of AQP4 labeling along astrocytic endfoot membranes facing capillary endothelial cells versus neuropil, was not significantly different between iNPH and REF subjects (Figure 3c ).
Considering all individuals, there was a highly significant positive correlation between AQP4 labeling toward endothelial membrane and neuropil, that is, low AQP4 labeling toward endothelium was accompanied by low AQP4 labeling toward neuropil and vice versa (Figure 3d ).
| AQP4 immunogold labeling versus age
Since mean age was higher in the iNPH group, the lower AQP4 labeling in iNPH might have been an age-effect. There was, however, not any significant association between age and AQP4 
| ICP scores versus AQP4 immunogold labeling in iNPH patients
The association between pulsatile and static ICP scores, and AQP4 immunogold labeling is presented in Table 4 . We found neither any significant correlation between the ICP scores and the AQP4 labeling toward endothelial cells or neuropil, nor any significant correlation between ICP scores and polarization index.
It should be noted, however, that all the 26 iNPH patients being clinical responders to surgery had pulsatile ICP scores above previously published threshold values (Eide & Sorteberg, 2010) . A hallmark of the healthy brain is the clustering of AQP4 water channels at the brain-blood and brain-liquor interfaces (Nagelhus et al., 1999; Nielsen et al., 1997) . Loss of AQP4 from perivascular astrocytic endfoot membranes is a key finding in patients with mesial temporal lobe epilepsy (Eid et al., 2005) , neuromyelitis optica (Misu et al., 2007) , ischemic stroke (Steiner et al., 2012; Stokum et al., 2015) , and Alzheimer's disease (Zeppenfeld et al., 2017) . Numerous studies using animal models conclude that loss or mislocalization of AQP4 affect disease development and survival (Nagelhus & Ottersen, 2013; Papadopoulos & Verkman, 2013) . This is the first study showing loss of AQP4 from perivascular astrocytic endfeet in iNPH using post-embedding immunogold EM, confirming a LM immunohistochemical report (Eide & Hansson, 2018) .
The high number of observations and an accurate quantitative approach make the data robust. A semiautomatic approach (Enger, 2017) was used to determine the number and distribution of the immunogold particles. The method combines manual segmentation of cell membranes with automated gold particle detection with high precision and a low false-positive detection rate (Enger, 2017) . Comparing with another immunogold analysis method based on ImageJ (Lauritzen et al., 2016) , the MATLAB based automated gold particle detection method added precision and efficiency to the analysis of the big data set in question.
AQP4 is confined to ependymal cells and to astrocytes in the brain, and have a unique subcellular distribution pattern in astrocytes, with a strong enrichment in astrocytic perivascular endfoot processes (Nielsen et al., 1997) . In humans, in contrast to rodents, AQP4 is also present in relatively high numbers in astrocyte membranes throughout the neuropil (Eidsvaag et al., 2017) . We previously reported that the AQP4 polarization index differed significantly between humans and rodents, with higher polarization of AQP4 toward astrocytic endfeet in rodents (Eidsvaag et al., 2017) . This study extend previous observations by showing no significant difference in AQP4 polarization index between iNPH and REF patients, even though perivascular AQP4 expression was significantly reduced in iNPH. Previous studies in rodents have disclosed reduced AQP4 polarization with increasing age (Kress et al., 2014) and following traumatic brain injury (Ren et al., 2013) .
Our material included 30 iNPH patients in whom 26 received surgical treatment and all 26 responded clinically to surgery. The 26 iNPH patients responding to surgery may thus be denoted "true" iNPH patients, or "definite" iNPH, as defined by the Japanese Guidelines of iNPH (Mori et al., 2012) . As the present patient material contained no shunt nonresponders, we cannot answer how AQP4 mislocalization relates to shunt response.
The control cohort included individuals who underwent surgery for epilepsy (nine patients), cerebral aneurysms (two patients), and brain tumor (one patients). Although our control tissue derives from patients with brain disorders, it was sampled from regions thought not to be part of the disease process per se. The controls showed similar AQP4 densities and distribution patterns independent of diagnosis, though statistical comparisons within the control cohort could not be done due to low patient numbers.
Parenchymal AQP4 immunoreactivity is upregulated with increasing age in normal human brains and in adults with hydrocephalus (Skjolding, Holst, Broholm, Laursen, & Juhler, 2013) , but reduced or even lost around Aβ deposits in Alzheimer's disease (Hoshi et al., 2012; Wilcock, Vitek, & Colton, 2009; Zeppenfeld et al., 2017) . Similarly, in infections, inflammation and brain injury there is a reduction and redistribution of AQP4 (Ren et al., 2013) .
Since mean age was higher in the iNPH than REF cohort it can be argued that loss of perivascular AQP4 is an age-effect. However, we found no association between age and endfoot AQ4 labeling in our sample, though the absence of significant correlation might be caused by statistical under powering. Neither did a light microscopy study of the postmortem frontal cortex of cognitively healthy humans find any difference in perivascular AQP4 expression between individuals of advanced age and young adults (Zeppenfeld et al., 2017) .
In rodents, loss of AQP4 is associated with water accumulation in the brain parenchyma (Haj-Yasein et al., 2011; Vindedal et al., 2016) , impaired perivascular CSF and interstitial fluid circulation, and hampered amyloid-β clearance (Iliff et al., 2012) . These findings are not secondary to disruption of the blood-brain barrier, as AQP4 deficient mice have normal blood-brain barrier integrity Saadoun et al., 2009) . Thus, loss of perivascular AQP4 is likely to have direct effects on perivascular fluid flow and brain water homeostasis.
We found a nonsignificant negative correlation between endfoot AQP4 expression and pulsatile ICP scores. It should be noted, however, that all 26 iNPH patients responding to surgery had pulsatile ICP scores above thresholds, as previously defined (Eide & Sorteberg, 2010) . The lack of significant correlation may thus be related to the low number of individuals with pulsatile ICP in the lower range.
Recently, a MRI study disclosed that iNPH patients have reduced glymphatic function along with enhanced accumulation and decreased clearance of an intrathecally administered contrast agent, gadobutrol (Eide & Ringstad, 2018; Ringstad et al., 2017) . The gadobutrol propa- Average ( the fluid and nutrient transfer at the capillary level as reflected by a long-lasting clinical improvement (Eide & Sorteberg, 2016) . The high concomitant occurrence of cardiovascular disease and diabetes mellitus in iNPH likely contribute to disease progress (Eide & Pripp, 2014) .
The clinical picture in iNPH shares several features and symptoms with Alzheimer's disease such as age, slow progression of cognitive decline, combined with gradual and progressive physical decline.
However, there are major differences between these disease entities, such as the early development of ventriculomegaly in iNPH as well as less prominent accumulation of amyloid-β plaques and neurofibrillary tangles (Hoshi et al., 2012) . Nevertheless, amyloid-β deposition is seen in iNPH, but less prominently so than in Alzheimer's disease (Hiraoka et al., 2015) . Furthermore, diversion of CSF exerts no effects on Alzheimer's disease but counteracts the symptoms of iNPH, at least for a few years (Eide & Sorteberg, 2016) . In addition, the observed reduction in AQP4 immunoreactivity of astrocytic perivascular endfeet surrounding microvessels in iNPH patients have not been demonstrated to prevail in Alzheimer's disease. In the latter cases, the AQP4 is only lost at blood vessels adjacent to amyloid deposits and related abnormalities (Zeppenfeld et al., 2017) .
It may be questioned how extensive loss of perivascular AQP4 that would be required to affect glymphatic function and impair glymphatic clearance in iNPH, as recently reported in MRI studies (Eide & Ringstad, 2018; Ringstad et al., 2017) . In this study, the loss of AQP4 at astrocytic endfeet facing endothelial cells was 16% at the group level. This magnitude of AQP4 decrease may not be sufficient to explain some of the pathological features of iNPH. It should be noted that iNPH is a chronic disease, evolving over months and years. Prolonged osmotic stress may over time result in glial dysfunction and thereby over time be of pathophysiological significance for development of iNPH. 
| CONCLUSIONS
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